| GTO ID | GTC2217 |
| Trial ID |
NCT04136171
|
| Disease |
Transthyretin Amyloid Cardiomyopathy
|
| Altered gene | TTR |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | AKCEA-TTR-LRx|Eplontersen|ION-682884|IONIS-TTR-LRx|ION-682884|Wainua |
| Location approved | US |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) |
| Year | 2020 |
| Country | Argentina|Australia|Austria|Belgium|Brazil|Canada|Czechia|Denmark|France|Germany|Greece|Israel|Italy|Japan|Poland|Portugal|Puerto Rico|Spain|Sweden|United Kingdom|United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ION-682884-CS2|2019-002835-27 |